Perioperative mortality following repair of abdominal aortic aneurysms: Application of a randomized clinical trial to real-world practice using a validated nationwide data set

Mahmoud Malas, Isibor Arhuidese, Umair Qazi, James Hamilton Black, Bruce Alan Perler, Julie A. Freischlag

Research output: Contribution to journalArticle

Abstract

OBJECTIVES To compare 30-day mortality from the recent Open Vs Endovascular Repair (OVER) Veterans Affairs Cooperative trial with results obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) and to assess temporal trends in perioperative mortality.

DESIGN, SETTING, AND PARTICIPANTS We analyzed data from 21 115 patients who received elective EVAR or open repair for asymptomatic infrarenal AAA between January 1, 2005, and December 31, 2011, in the NSQIP database.We used ?2 and t tests to compare perioperative mortality between groups. Logistic regression was used to analyze perioperative mortality, adjusting for age, sex, race, and comorbidities. The outcomes of the OVER trial were then compared with the national estimates obtained from the NSQIP.

MAIN OUTCOMES AND MEASURES Death within 30 days of surgery.

RESULTS Perioperative mortality was 3.7%(95%CI, 3.2%-4.3%) after open repair and 1.3% (95%CI, 1.2%-1.5%) after EVAR. There was a 70% reduction in operative mortality after EVAR compared with open repair (adjusted odds ratio [aOR], 0.30; 95%CI, 0.25-0.38; P <.001). Mortality was significantly lower in men compared with women (aOR, 0.73; 95%CI, 0.57-0.92; P = .009). Thirty-day mortality in the NSQIP cohort was higher than that reported in the OVER trial for both EVAR and open repair (EVAR, 1.3%vs 0.2%; open, 3.7%vs 2.3%). There was an increase in the proportion of patients who received EVAR during the 7 years studied (65%in 2005 and 80% in 2011). There has been no significant decrease in perioperative mortality during these years (P > .05).

CONCLUSIONS AND RELEVANCE Perioperative mortality reported by the OVER trial is significantly lower than outcomes from practices outside the restriction of randomized clinical trials.We attribute this difference to the fact that the OVER trial excluded high-risk patients deemed unfit for open repair. This finding supports the need for individualized assessment of risk and treatment selection for patients with infrarenal AAA. There has been no change in perioperative mortality after EVAR in recent years despite improvements in techniques, devices, and proficiency.

IMPORTANCE Because of the restrictions applied to the conduct of randomized clinical trials, the risks reported in their comparison of open and endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) may not be applicable to real-world vascular surgical practice. The magnitude of this deviation is indeterminate.

Original languageEnglish (US)
Pages (from-to)1260-1265
Number of pages6
JournalJAMA Surgery
Volume149
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Abdominal Aortic Aneurysm
Randomized Controlled Trials
Mortality
Aneurysm
Quality Improvement
Needs Assessment
Datasets
Veterans
Ambulatory Surgical Procedures
Patient Selection
Blood Vessels
Comorbidity
Logistic Models
Odds Ratio
Outcome Assessment (Health Care)
Databases
Equipment and Supplies

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Perioperative mortality following repair of abdominal aortic aneurysms : Application of a randomized clinical trial to real-world practice using a validated nationwide data set. / Malas, Mahmoud; Arhuidese, Isibor; Qazi, Umair; Black, James Hamilton; Perler, Bruce Alan; Freischlag, Julie A.

In: JAMA Surgery, Vol. 149, No. 12, 01.12.2014, p. 1260-1265.

Research output: Contribution to journalArticle

@article{2fad0307dd5342338395e51b6aad0be4,
title = "Perioperative mortality following repair of abdominal aortic aneurysms: Application of a randomized clinical trial to real-world practice using a validated nationwide data set",
abstract = "OBJECTIVES To compare 30-day mortality from the recent Open Vs Endovascular Repair (OVER) Veterans Affairs Cooperative trial with results obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) and to assess temporal trends in perioperative mortality.DESIGN, SETTING, AND PARTICIPANTS We analyzed data from 21 115 patients who received elective EVAR or open repair for asymptomatic infrarenal AAA between January 1, 2005, and December 31, 2011, in the NSQIP database.We used ?2 and t tests to compare perioperative mortality between groups. Logistic regression was used to analyze perioperative mortality, adjusting for age, sex, race, and comorbidities. The outcomes of the OVER trial were then compared with the national estimates obtained from the NSQIP.MAIN OUTCOMES AND MEASURES Death within 30 days of surgery.RESULTS Perioperative mortality was 3.7{\%}(95{\%}CI, 3.2{\%}-4.3{\%}) after open repair and 1.3{\%} (95{\%}CI, 1.2{\%}-1.5{\%}) after EVAR. There was a 70{\%} reduction in operative mortality after EVAR compared with open repair (adjusted odds ratio [aOR], 0.30; 95{\%}CI, 0.25-0.38; P <.001). Mortality was significantly lower in men compared with women (aOR, 0.73; 95{\%}CI, 0.57-0.92; P = .009). Thirty-day mortality in the NSQIP cohort was higher than that reported in the OVER trial for both EVAR and open repair (EVAR, 1.3{\%}vs 0.2{\%}; open, 3.7{\%}vs 2.3{\%}). There was an increase in the proportion of patients who received EVAR during the 7 years studied (65{\%}in 2005 and 80{\%} in 2011). There has been no significant decrease in perioperative mortality during these years (P > .05).CONCLUSIONS AND RELEVANCE Perioperative mortality reported by the OVER trial is significantly lower than outcomes from practices outside the restriction of randomized clinical trials.We attribute this difference to the fact that the OVER trial excluded high-risk patients deemed unfit for open repair. This finding supports the need for individualized assessment of risk and treatment selection for patients with infrarenal AAA. There has been no change in perioperative mortality after EVAR in recent years despite improvements in techniques, devices, and proficiency.IMPORTANCE Because of the restrictions applied to the conduct of randomized clinical trials, the risks reported in their comparison of open and endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) may not be applicable to real-world vascular surgical practice. The magnitude of this deviation is indeterminate.",
author = "Mahmoud Malas and Isibor Arhuidese and Umair Qazi and Black, {James Hamilton} and Perler, {Bruce Alan} and Freischlag, {Julie A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1001/jamasurg.2014.275",
language = "English (US)",
volume = "149",
pages = "1260--1265",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Perioperative mortality following repair of abdominal aortic aneurysms

T2 - Application of a randomized clinical trial to real-world practice using a validated nationwide data set

AU - Malas, Mahmoud

AU - Arhuidese, Isibor

AU - Qazi, Umair

AU - Black, James Hamilton

AU - Perler, Bruce Alan

AU - Freischlag, Julie A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - OBJECTIVES To compare 30-day mortality from the recent Open Vs Endovascular Repair (OVER) Veterans Affairs Cooperative trial with results obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) and to assess temporal trends in perioperative mortality.DESIGN, SETTING, AND PARTICIPANTS We analyzed data from 21 115 patients who received elective EVAR or open repair for asymptomatic infrarenal AAA between January 1, 2005, and December 31, 2011, in the NSQIP database.We used ?2 and t tests to compare perioperative mortality between groups. Logistic regression was used to analyze perioperative mortality, adjusting for age, sex, race, and comorbidities. The outcomes of the OVER trial were then compared with the national estimates obtained from the NSQIP.MAIN OUTCOMES AND MEASURES Death within 30 days of surgery.RESULTS Perioperative mortality was 3.7%(95%CI, 3.2%-4.3%) after open repair and 1.3% (95%CI, 1.2%-1.5%) after EVAR. There was a 70% reduction in operative mortality after EVAR compared with open repair (adjusted odds ratio [aOR], 0.30; 95%CI, 0.25-0.38; P <.001). Mortality was significantly lower in men compared with women (aOR, 0.73; 95%CI, 0.57-0.92; P = .009). Thirty-day mortality in the NSQIP cohort was higher than that reported in the OVER trial for both EVAR and open repair (EVAR, 1.3%vs 0.2%; open, 3.7%vs 2.3%). There was an increase in the proportion of patients who received EVAR during the 7 years studied (65%in 2005 and 80% in 2011). There has been no significant decrease in perioperative mortality during these years (P > .05).CONCLUSIONS AND RELEVANCE Perioperative mortality reported by the OVER trial is significantly lower than outcomes from practices outside the restriction of randomized clinical trials.We attribute this difference to the fact that the OVER trial excluded high-risk patients deemed unfit for open repair. This finding supports the need for individualized assessment of risk and treatment selection for patients with infrarenal AAA. There has been no change in perioperative mortality after EVAR in recent years despite improvements in techniques, devices, and proficiency.IMPORTANCE Because of the restrictions applied to the conduct of randomized clinical trials, the risks reported in their comparison of open and endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) may not be applicable to real-world vascular surgical practice. The magnitude of this deviation is indeterminate.

AB - OBJECTIVES To compare 30-day mortality from the recent Open Vs Endovascular Repair (OVER) Veterans Affairs Cooperative trial with results obtained from the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) and to assess temporal trends in perioperative mortality.DESIGN, SETTING, AND PARTICIPANTS We analyzed data from 21 115 patients who received elective EVAR or open repair for asymptomatic infrarenal AAA between January 1, 2005, and December 31, 2011, in the NSQIP database.We used ?2 and t tests to compare perioperative mortality between groups. Logistic regression was used to analyze perioperative mortality, adjusting for age, sex, race, and comorbidities. The outcomes of the OVER trial were then compared with the national estimates obtained from the NSQIP.MAIN OUTCOMES AND MEASURES Death within 30 days of surgery.RESULTS Perioperative mortality was 3.7%(95%CI, 3.2%-4.3%) after open repair and 1.3% (95%CI, 1.2%-1.5%) after EVAR. There was a 70% reduction in operative mortality after EVAR compared with open repair (adjusted odds ratio [aOR], 0.30; 95%CI, 0.25-0.38; P <.001). Mortality was significantly lower in men compared with women (aOR, 0.73; 95%CI, 0.57-0.92; P = .009). Thirty-day mortality in the NSQIP cohort was higher than that reported in the OVER trial for both EVAR and open repair (EVAR, 1.3%vs 0.2%; open, 3.7%vs 2.3%). There was an increase in the proportion of patients who received EVAR during the 7 years studied (65%in 2005 and 80% in 2011). There has been no significant decrease in perioperative mortality during these years (P > .05).CONCLUSIONS AND RELEVANCE Perioperative mortality reported by the OVER trial is significantly lower than outcomes from practices outside the restriction of randomized clinical trials.We attribute this difference to the fact that the OVER trial excluded high-risk patients deemed unfit for open repair. This finding supports the need for individualized assessment of risk and treatment selection for patients with infrarenal AAA. There has been no change in perioperative mortality after EVAR in recent years despite improvements in techniques, devices, and proficiency.IMPORTANCE Because of the restrictions applied to the conduct of randomized clinical trials, the risks reported in their comparison of open and endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) may not be applicable to real-world vascular surgical practice. The magnitude of this deviation is indeterminate.

UR - http://www.scopus.com/inward/record.url?scp=84919683980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919683980&partnerID=8YFLogxK

U2 - 10.1001/jamasurg.2014.275

DO - 10.1001/jamasurg.2014.275

M3 - Article

C2 - 25337871

AN - SCOPUS:84919683980

VL - 149

SP - 1260

EP - 1265

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 12

ER -